Tuberculosis, Multidrug-Resistant
"Tuberculosis, Multidrug-Resistant" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS.
Descriptor ID |
D018088
|
MeSH Number(s) |
C01.252.410.040.552.846.775
|
Concept/Terms |
Tuberculosis, Multidrug-Resistant- Tuberculosis, Multidrug-Resistant
- Multidrug-Resistant Tuberculosis
- Tuberculosis, Multidrug Resistant
- Tuberculosis, MDR
- MDR Tuberculosis
- Tuberculosis, Multi-Drug Resistant
- Multi-Drug Resistant Tuberculosis
- Tuberculosis, Multi Drug Resistant
|
Below are MeSH descriptors whose meaning is more general than "Tuberculosis, Multidrug-Resistant".
Below are MeSH descriptors whose meaning is more specific than "Tuberculosis, Multidrug-Resistant".
This graph shows the total number of publications written about "Tuberculosis, Multidrug-Resistant" by people in UAMS Profiles by year, and whether "Tuberculosis, Multidrug-Resistant" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2025 | 1 | 0 | 1 | 2023 | 1 | 0 | 1 | 2022 | 1 | 0 | 1 | 2019 | 1 | 0 | 1 | 2018 | 1 | 0 | 1 | 2017 | 2 | 0 | 2 | 2016 | 1 | 0 | 1 | 2015 | 3 | 1 | 4 | 2014 | 1 | 0 | 1 | 2013 | 1 | 0 | 1 | 2012 | 1 | 0 | 1 | 2007 | 0 | 1 | 1 | 2006 | 1 | 0 | 1 | 2001 | 1 | 0 | 1 | 1999 | 1 | 0 | 1 | 1996 | 1 | 0 | 1 | 1995 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Tuberculosis, Multidrug-Resistant" by people in Profiles over the past ten years.
-
Kaur P, Chaisson LH, Kiragu ZW, Buddadhumaruk P, Austin AF, Gao Y, Wirtz VJ, Arbeit RD, Fetalvero KB, Nguyen HB, Nguyen NV, Ha H, Eisenach K, Walter ND, Mitnick CD, Gler MTS, Phan H, Nahid P, Phillips PPJ, Horsburgh CR, Vel?squez GE. Study protocol for a duration-randomized clinical trial to determine the optimal length of treatment for multidrug-resistant tuberculosis with a 5-drug regimen: The DRAMATIC trial. Contemp Clin Trials. 2025 May; 152:107875.
-
Syed RR, Catanzaro DG, Colman RE, Cooney CG, Linger Y, Kukhtin AV, Holmberg RC, Norville R, Crudu V, Ciobanu N, Codreanu A, Seifert M, Hillery N, Chiles P, Catanzaro A, Rodwell TC. Clinical Evaluation of the XDR-LFC Assay for the Molecular Detection of Isoniazid, Rifampin, Fluoroquinolone, Kanamycin, Capreomycin, and Amikacin Drug Resistance in a Prospective Cohort. J Clin Microbiol. 2023 03 23; 61(3):e0147822.
-
Smith-Jeffcoat SE, Eisenach KD, Joloba M, Ssengooba W, Namaganda C, Nsereko M, Okware B, Cavanaugh JS, Cegielski JP. Quantification of multidrug-resistant M. tuberculosis bacilli in sputum during the first 8 weeks of treatment. Int J Tuberc Lung Dis. 2022 Nov 01; 26(11):1058-1064.
-
Colman RE, Mace A, Seifert M, Hetzel J, Mshaiel H, Suresh A, Lemmer D, Engelthaler DM, Catanzaro DG, Young AG, Denkinger CM, Rodwell TC. Whole-genome and targeted sequencing of drug-resistant Mycobacterium tuberculosis on the iSeq100 and MiSeq: A performance, ease-of-use, and cost evaluation. PLoS Med. 2019 04; 16(4):e1002794.
-
Peloquin CA, Phillips PPJ, Mitnick CD, Eisenach K, Patientia RF, Lecca L, Gotuzzo E, Gandhi NR, Butler D, Diacon AH, Martel B, Santillan J, Hunt KR, Vargas D, von Groote-Bidlingmaier F, Seas C, Dianis N, Moreno-Martinez A, Kaur P, Horsburgh CR. Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis. Antimicrob Agents Chemother. 2018 10; 62(10).
-
Bouton TC, Phillips PPJ, Mitnick CD, Peloquin CA, Eisenach K, Patientia RF, Lecca L, Gotuzzo E, Gandhi NR, Butler D, Diacon AH, Martel B, Santillan J, Hunt KR, Vargas D, von Groote-Bidlingmaier F, Seas C, Dianis N, Moreno-Martinez A, Horsburgh CR. An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial. Trials. 2017 Nov 25; 18(1):563.
-
Georghiou SB, Seifert M, Catanzaro DG, Garfein RS, Rodwell TC. Increased Tuberculosis Patient Mortality Associated with Mycobacterium tuberculosis Mutations Conferring Resistance to Second-Line Antituberculous Drugs. J Clin Microbiol. 2017 06; 55(6):1928-1937.
-
Seifert M, Ajbani K, Georghiou SB, Catanzaro D, Rodrigues C, Crudu V, Victor TC, Garfein RS, Catanzaro A, Rodwell TC. A performance evaluation of MTBDRplus version 2 for the diagnosis of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2016 May; 20(5):631-7.
-
Yamada S, Riklon S, Maskarinec GG. Ethical Responsibility for the Social Production of Tuberculosis. J Bioeth Inq. 2016 Mar; 13(1):57-64.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|